PLx Pharma (NASDAQ:PLXP) reported quarterly losses of $(0.28) per share which missed the analyst consensus estimate of $(0.22) by 27.27 percent. This is a 37.78 percent increase over losses of $(0.45) per share from the same period last year.
Novan Announces Strategic Priorities and Outlines Key Milestones
– Company planning for three potential New Drug Application (NDA) filings in three years with the first submission expected in Q3 2022 for lead program SB206 in molluscum contagiosum –
– Late-stage
